复星医药控股子公司拟出资14.12亿元控股投资绿谷医药

Core Viewpoint - Fosun Pharma aims to enhance its product pipeline in the central nervous system treatment area by acquiring a controlling stake in Green Valley Pharmaceutical for a total investment of 1.412 billion yuan [1] Group 1: Acquisition Details - Fosun Pharma's subsidiary plans to invest 1.412 billion yuan to gain control over Green Valley Pharmaceutical [1] - Following the acquisition, Green Valley Pharmaceutical will become a subsidiary of Fosun Pharma, and its core drug, mannitol sodium capsules, will be included in Fosun's innovative drug pipeline [1] Group 2: Product Information - Mannitol sodium capsules are primarily used for the treatment of mild to moderate Alzheimer's disease [1] - Due to the expiration of the registration approval, commercial production of mannitol sodium capsules will not commence until November 2024, pending the completion of post-marketing confirmatory clinical trials and approval from the national drug review authority [1] - As of the announcement date, the post-marketing confirmatory clinical trials are currently underway [1]